patritumab deruxtecan
Selected indexed studies
- Patritumab deruxtecan induces immunogenic cell death. (Oncoimmunology, 2025) [PMID:40458967]
- Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer. (Cancer Discov, 2022) [PMID:34548309]
- HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR-mutated NSCLC after a third-generation EGFR TKI. (Future Oncol, 2024) [PMID:38095056]
_Worker-drafted node — pending editorial review._
Connections
patritumab deruxtecan is a side effect of
Sources
- Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC. (2024) pubmed
- Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non-Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy. (2025) pubmed
- Patritumab deruxtecan induces immunogenic cell death. (2025) pubmed
- Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer. (2022) pubmed
- HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR-mutated NSCLC after a third-generation EGFR TKI. (2024) pubmed
- HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy. (2023) pubmed
- Patritumab deruxtecan in breast cancer treatment: a drug evaluation. (2025) pubmed
- Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial. (2023) pubmed
- Patritumab deruxtecan in HR(+)HER2(-) advanced breast cancer: a phase 2 trial. (2025) pubmed
- Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial. (2025) pubmed